NS-11821
NS-11821, or NS11821 is a GABA A receptor positive allosteric modulator and nonbenzodiazepine which was under development for the treatment of anxiety disorders and CNS disorders but was never marketed.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
NS-11821, or NS11821 is a GABA A receptor positive allosteric modulator and nonbenzodiazepine which was under development for the treatment of anxiety disorders and CNS disorders but was never marketed. It is taken orally. The drug is a subunit-selective partial positive allosteric modulator of the GABA A receptor.
More specifically, it shows affinity (K i ) values of 1.6 nM at α 1 , 9.7 nM at α 2 , 3.8 nM at α 3 , and 2.5 nM at α 5 , whereas it shows ( ) values of (4%) at α 1 , 59 nM (17%) at α 2 , 73 nM (40%) at α 3 , and 44 nM (41%) at α 5 . Based on animal studies, this is expected to translate into a profile of anxiolytic effects with low propensity for sedation.
Clinical findings of NS-11821 in humans have been described. NS-11821 was under development by NeuroSearch. It reached phase 1 clinical trials for both anxiety disorders and CNS disorders prior to the discontinuation of its development in 2017.
The chemical structure of NS-11821 does not yet appear to have been disclosed.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1357954390 under CC BY-SA 4.0; modifications have been made.